ReviewMolecules (Basel, Switzerland)2015
Pro-moieties of antimicrobial peptide prodrugs.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A Review on Bacteriocin Extraction Techniques from Lactic Acid Bacteria.Probiotics and antimicrobial proteins · 2025Review
- Structure-activity relationships of antibacterial peptides.Microbial biotechnology · 2023Review
- PEGylated Oligothioetheramide Prodrugs Activated by Host Serum Proteases.Chembiochem : a European journal of chemical biology · 2021Article
- Selective Bacterial Targeting and Infection-Triggered Release of Antibiotic Colistin Conjugates.Angewandte Chemie (International ed. in English) · 2021Article
- Novel phenolic antimicrobials enhanced activity of iminodiacetate prodrugs against biofilm and planktonic bacteria.Chemical biology & drug design · 2021Article
- Identification of a Novel Cathelicidin from theToxins · 2020Article
- Synergies with and Resistance to Membrane-Active Peptides.Antibiotics (Basel, Switzerland) · 2020Review
- Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones.Pharmaceutics · 2020Review
- Potential factors contributing to the poor antimicrobial efficacy of SAAP-148 in a rat wound infection model.Annals of clinical microbiology and antimicrobials · 2019Article
- Snake Venom Cathelicidins as Natural Antimicrobial Peptides.Frontiers in pharmacology · 2019Review
- Article
- An acidic model pro-peptide affects the secondary structure, membrane interactions and antimicrobial activity of a crotalicidin fragment.Scientific reports · 2018Article
- Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus.Materials (Basel, Switzerland) · 2018Review
- Antibiotic resistance: a rundown of a global crisis.Infection and drug resistance · 2018Review
- Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.Molecules (Basel, Switzerland) · 2017Review
- Host defense antimicrobial peptides as antibiotics: design and application strategies.Current opinion in chemical biology · 2017Review
- Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.Antimicrobial agents and chemotherapy · 2016Article
- Antimicrobial peptides in 2014.Pharmaceuticals (Basel, Switzerland) · 2015Review
- Cecropins from Plutella xylostella and Their Interaction with Metarhizium anisopliae.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) are a promising class of antimicrobial agents that have been garnering increasing attention as resistance renders many conventional antibiotics ineffective. Extensive research has resulted in a large library of highly-active AMPs. However, several issues serve as an impediment to their clinical development, not least the issue of host toxicity. An approach that may allow otherwise cytotoxic AMPs to be used is to deliver them as a prodrug, targeting antimicrobial activity and limiting toxic effects on the host. The varied library of AMPs is complemented by a selection of different possible pro-moieties, each with their own characteristics. This review deals with the different pro-moieties that have been used with AMPs and discusses the merits of each.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.